Adavosertib is under clinical development by AstraZeneca and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Mathew Knowles, father of Beyoncé and Solange, shares his journey as both a music legend and a breast cancer survivor.

The phase III SOUND trial randomized patients with early breast cancer and a negative axillary ultrasound to SLNB or no ...

Feedback from the EU indicated that the trial results, which the application was based on, showed that the drug did not ...

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) said that they have voluntarily withdrawn their ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization ...

Reports indicate that around 20 senior managers and nearly 110 executives have been dismissed from various levels in the ...

AstraZeneca has pulled its European marketing authorisation application for its non-small cell lung cancer treatment based on ...

While the application for datopotamab deruxtecan in NSCLC has been withdrawn, another application by AstraZeneca and Daiichi Sankyo for the drug's use in hormone receptor (HR)-positive, HER2-negative ...